The compound
Tremfya® (guselkumab)– An investigational antibody targeting IL-23
Tremfya® (guselkumab) is a fully human anti-interleukin (IL)-23 monoclonal antibody developed by Janssen. The HuCAL antibody library technology was used to generate the guselkumab antibody under license from MorphoSys. IL-23 is a pro-inflammatory protein which has been identified as a cytokine in autoimmune diseases. According to scientific literature, IL-23 is found in the skin of patients with psoriasis and in other inflammatory diseases. It is therefore considered a potential treatment target for inflammatory diseases.
Guselkumab is being developed by MorphoSys’s licensee Janssen for the treatment of moderate to severe plaque psoriasis and for patients with active psoriatic arthritis (PsA), and for several other indications.